← Back to Clinical Trials
Recruiting NCT03642795

NCT03642795 Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03642795
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Nīmes
Condition Rheumatoid Polyarthritis
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2022-06-23
Primary Completion 2029-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Questionnaire

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2022-06-23 with a primary completion date of 2029-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to develop a French language version of the Compliance-Questionnaire-Rheumatology for use in French and Francophone rheumatology services

Eligibility Criteria

Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient is at least 18 years old * The patient has rheumatoid polyarthritis as defined by the ACR-EULAR 2010 criteria, treated orally or subcutaneously with MTX for at least 3 months with a stable (unchanged) dosage for at least 1 month, and a stable (unchanged) route of administration for at least 1 month. And no planned change in Methotrexate intake at least until the second study visit. Other treatments at the same time are authorized Exclusion Criteria: * The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * The subject has a contraindication to taking methotrexate (including a patient with a desire to become pregnant).

Contact & Investigator

Central Contact

Cécile Gaujoux Viala, MD

✉ cecile.gaujoux.viala@chu-nimes.fr

📞 04 66 68 31 20

Frequently Asked Questions

Who can join the NCT03642795 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Polyarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03642795 currently recruiting?

Yes, NCT03642795 is actively recruiting participants. Contact the research team at cecile.gaujoux.viala@chu-nimes.fr for enrollment information.

Where is the NCT03642795 trial being conducted?

This trial is being conducted at Bordeaux, France, Montpellier, France, Nîmes, France, Toulouse, France.

Who is sponsoring the NCT03642795 clinical trial?

NCT03642795 is sponsored by Centre Hospitalier Universitaire de Nīmes. The trial plans to enroll 150 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology